Bromodomain inhibition has emerged as a pivotal strategy in cancer research by targeting the epigenetic mechanisms that govern gene expression. Bromodomains are protein modules that recognise ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that two ...
OPN-6602 is Currently in a Phase 1 Clinical Trial for Relapsed/Refractory Multiple Myeloma SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–February 12, 2025– Opna Bio, a clinical-stage biopharmaceutical ...
TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung ...
Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, today announced that OPN-2853, a bromodomain and extra-terminal motif (BET ...
Basel, June 04, 2025 – TOLREMO therapeutics AG (TOLREMO), a clinical stage biotechnology company pioneering non-oncogene addiction in cancer, today announced data from its ongoing Phase I study of ...
Effect of a novel compound that covalently binds to the HPV16 E6 protein on proliferation of HPV-associated cervical and oropharyngeal cancer cells through p53 effector pathway activation. Effects of ...
Bromodomains are epigenetic reader proteins that recognize acetylated histone tails, playing a key role in chromatin remodeling and gene regulation. Through these mechanisms, they influence the ...
The FDA granted orphan drug designation to zavabresib, an investigational therapy for the treatment of myelofibrosis, a rare ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results